瓦克赛特生物

最新新闻

• 评级变动
  BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $89
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $134
  \u5e02\u573a\u8d44\u8baf · 2025/10/3
• 评级变动
  Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• 评级变动
  BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $133
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $75
  \u5e02\u573a\u8d44\u8baf · 2026/2/25
• 评级变动
  Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $110
  \u5e02\u573a\u8d44\u8baf · 2026/1/7
• Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $125
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $163
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $85
  \u5e02\u573a\u8d44\u8baf · 2025/10/16
• 评级变动
  Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $163
  \u5e02\u573a\u8d44\u8baf · 2025/8/18
• 评级变动
  Evercore Maintains Vaxcyte(PCVX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/21
• 评级变动
  Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $90
  \u5e02\u573a\u8d44\u8baf · 2025/12/9
• Jefferies Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $146
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Goldman Sachs Maintains Vaxcyte(PCVX.US) With Hold Rating, Maintains Target Price $67
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $85
  \u5e02\u573a\u8d44\u8baf · 2026/2/13
• 评级变动
  A Quick Look at Today's Ratings for Vaxcyte(PCVX.US), With a Forecast Between $67 to $133
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2025/11/5

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。